Logo

Predictive Oncology: Nancy Chung-Welch, Charles Nuzum, Greg St. Clair

Jul 14, 2020

Predictive Oncology has appointed Nancy Chung-Welch, Charles Nuzum, and Greg St. Clair as independent directors. While Nuzum will serve on Predictive's audit committee, the firm noted that the other directors will join committees as soon as possible. 

Chung-Welch currently serves as an independent consultant advising life science companies and institutional investors. She previously served as director of business development at Cell Signaling Technology, as well as a director of business development at Thermo Fisher Scientific. She has also served as a technical marketing manager at Fisher Scientific.

Nuzum currently provides project-based financial consulting services to companies including McKesson, BioMarin, and AutoDesk. He serves on the board of directors of Dakshidin, NanoSynx, and Worldwide Structures. He previously cofounded and served as CFO of Tyburn Group. Prior to Tyburn, Nuzum served as controller of Merck KgaA pharmaceutical manufacturing subsidiary Dely. Before working at Dely, he served as cofounder, executive VP, and CFO of SCV Financial Services. 

St. Clair is the founder and managing member of SunStone Consulting. Prior to SunStone, he served as national VP of CGI, ImrGlobal, and Orion Consulting. He also served as a national director for Coopers & Lybrand. 

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.